Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

viatris healthcare limited - tolcapone - parkinsonsveiki - anti-parkinson lyf, Önnur dopaminergic lyfjum - tasmar er ætlað ásamt algengari / benserazide eða algengari / ddc hemli til að nota í sjúklinga með algengari-móttækilegur sjálfvakin parkinsonsveiki og mótor sveiflur, sem tókst ekki að svara eða þola af öðrum katekóllausn-o-methyltransferase (comt) hemlar. vegna hættu hugsanlega banvæn, bráð lifur meiðslum, tasmar ætti ekki að vera talin fyrsta lína viðbót meðferð til að algengari / benserazide eða algengari / ddc hemli. Þar tasmar skal aðeins notaður í ásamt algengari / benserazide og algengari / ddc hemli, ávísun fyrir þessum algengari undirbúningur er einnig við til þeirra samhliða nota með tasmar.

Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

novartis europharm limited  - siponimod fúmarsýru - heila-og mænusigg, köstum tilkynnt - valdar ónæmisbælandi lyf - mayzent er ætlað fyrir meðferð fullorðinn sjúklinga með efri framsækið heila-og mænusigg (spms) með virk sjúkdómur sést af köst eða hugsanlegur aðgerðir æsandi virkni.

Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dímetýl fúmarat - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi lyf - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

merck europe b.v. - tepotinib hydrochloride monohydrate - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

novartis europharm limited - asciminib hydrochloride - kyrningahvítblæði, mergbreytilegt, langvinnt, bcr-abl jákvætt - Æxlishemjandi lyf - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab* - desfluranum inn - innöndunargufa, gegndreyptur stabbi

Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - pregabalinum inn - hart hylki - 25 mg

Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - pregabalinum inn - hart hylki - 75 mg

Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - pregabalinum inn - hart hylki - 150 mg